Pyridam Farma Tbk (JK:PYFA) — Stock Price
Pyridam Farma Tbk (JK:PYFA) is currently trading at Rp218.00 IDR, up 0.00% today. Over the past 52 weeks, shares have ranged between Rp171.00 and Rp645.00. This page tracks Pyridam Farma Tbk's live share price on the JK exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market cap of Pyridam Farma Tbk.
Pyridam Farma Tbk (PYFA) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Pyridam Farma Tbk's daily closing share price and trading volume on the JK exchange over the past year, giving a clear view of recent price momentum and liquidity.
Pyridam Farma Tbk Income Statement — Revenue, Profit & Earnings by Year
Pyridam Farma Tbk's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | Rp1.92 Trillion | Rp702.07 Billion | Rp715.43 Billion | Rp630.53 Billion | Rp277.40 Billion |
| Cost of Revenue | Rp1.38 Trillion | Rp406.75 Billion | Rp464.58 Billion | Rp385.95 Billion | Rp113.51 Billion |
| Gross Profit | Rp536.48 Billion | Rp295.32 Billion | Rp250.84 Billion | Rp244.58 Billion | Rp163.89 Billion |
| Research & Development | Rp17.62 Billion | Rp17.77 Billion | Rp11.28 Billion | Rp573.44 Million | Rp0.00 |
| SG&A | Rp74.25 Billion | Rp31.28 Billion | Rp27.12 Billion | Rp20.59 Billion | Rp11.89 Billion |
| Total Operating Expenses | Rp643.36 Billion | Rp293.44 Billion | Rp255.26 Billion | Rp193.47 Billion | Rp132.49 Billion |
| Operating Income | Rp-106.88 Billion | Rp1.88 Billion | Rp345.86 Billion | Rp51.90 Billion | Rp32.14 Billion |
| EBITDA | Rp-30.72 Billion | Rp60.70 Billion | Rp421.42 Billion | Rp83.74 Billion | Rp41.28 Billion |
| EBIT | Rp-100.95 Billion | Rp3.25 Billion | Rp350.17 Billion | Rp52.19 Billion | Rp32.21 Billion |
| Interest Expense | Rp225.98 Billion | Rp86.50 Billion | Rp86.91 Billion | Rp41.93 Billion | Rp2.56 Billion |
| Income Before Tax | Rp-313.14 Billion | Rp-83.25 Billion | Rp263.08 Billion | Rp8.81 Billion | Rp29.64 Billion |
| Income Tax Expense | Rp17.10 Billion | Rp1.98 Billion | Rp-12.39 Billion | Rp3.33 Billion | Rp7.54 Billion |
| Net Income | Rp-330.25 Billion | Rp-85.22 Billion | Rp275.24 Billion | Rp5.48 Billion | Rp22.10 Billion |
Pyridam Farma Tbk Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Pyridam Farma Tbk's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | Rp5.81 Trillion | Rp1.52 Trillion | Rp1.52 Trillion | Rp806.22 Billion | Rp228.58 Billion |
| Total Current Assets | Rp1.54 Trillion | Rp570.54 Billion | Rp540.99 Billion | Rp326.43 Billion | Rp129.34 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | Rp1.64 Billion | Rp0.00 | — | — | — |
| Net Receivables | Rp652.96 Billion | Rp204.50 Billion | Rp151.76 Billion | Rp100.99 Billion | Rp60.33 Billion |
| Inventory | Rp457.17 Billion | Rp225.48 Billion | Rp210.19 Billion | Rp145.94 Billion | Rp51.04 Billion |
| Property, Plant & Equipment | Rp1.53 Trillion | Rp767.80 Billion | Rp846.69 Billion | Rp386.76 Billion | Rp96.25 Billion |
| Goodwill | Rp1.71 Trillion | Rp42.45 Billion | Rp0.00 | Rp42.45 Billion | — |
| Total Liabilities | Rp4.77 Trillion | Rp1.16 Trillion | Rp1.08 Trillion | Rp639.12 Billion | Rp70.94 Billion |
| Total Current Liabilities | Rp1.20 Trillion | Rp293.71 Billion | Rp297.39 Billion | Rp251.84 Billion | Rp44.75 Billion |
| Long-term Debt | Rp2.82 Trillion | Rp830.41 Billion | Rp742.02 Billion | Rp354.01 Billion | Rp3.91 Billion |
| Net Debt | Rp3.52 Trillion | Rp897.02 Billion | Rp773.46 Billion | Rp401.08 Billion | Rp25.88 Billion |
| Total Stockholder Equity | Rp1.04 Trillion | Rp356.83 Billion | Rp442.13 Billion | Rp167.10 Billion | Rp157.63 Billion |
| Retained Earnings | Rp-44.80 Billion | Rp285.45 Billion | Rp370.67 Billion | Rp95.43 Billion | Rp89.95 Billion |
Pyridam Farma Tbk Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Pyridam Farma Tbk generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | Rp-141.04 Billion | Rp-103.98 Billion | Rp275.24 Billion | Rp39.59 Billion | Rp1.11 Billion |
| Capital Expenditures | Rp135.22 Billion | Rp23.66 Billion | Rp46.47 Billion | Rp222.03 Billion | Rp7.84 Billion |
| Free Cash Flow | Rp-276.26 Billion | Rp-127.64 Billion | Rp228.77 Billion | Rp-182.45 Billion | Rp-6.72 Billion |
| Investing Cash Flow | Rp-2.56 Trillion | Rp-22.46 Billion | Rp-243.00 Billion | Rp-371.56 Billion | Rp-6.58 Billion |
| Financing Cash Flow | Rp2.95 Trillion | Rp79.84 Billion | Rp326.36 Billion | Rp370.07 Billion | Rp9.62 Billion |
| Dividends Paid | Rp31.63 Billion | Rp0.00 | — | — | Rp0.00 |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | — | Rp57.45 Billion | Rp71.25 Billion | Rp31.54 Billion | Rp9.07 Billion |
| Change in Cash | Rp248.72 Billion | Rp-46.61 Billion | Rp88.85 Billion | Rp38.10 Billion | Rp4.34 Billion |
Pyridam Farma Tbk Earnings History — EPS Actual vs. Analyst Estimates
Track Pyridam Farma Tbk's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 01, 2023 | -45.55 | — | — |
| Apr 06, 2023 | -25.26 | — | — |
| Dec 31, 2022 | -25.26 | — | — |
| Nov 30, 2022 | 522.73 | — | — |
| Aug 31, 2022 | 12.25 | — | — |
| Jun 02, 2022 | -19.60 | — | — |
| Dec 31, 2021 | -19.60 | — | — |
| Nov 30, 2021 | 8.59 | — | — |